Merck for Mothers (Merck is known as MSD outside the United States and Canada)

Effective September 25, 2015, the Merck for Mothers Investigator Initiated Studies Program (IISP) Committee will accept proposals within our current areas of interest (AOI) up to February 16, 2016. This is a competitive process, with limited monetary funding available to support the budget for the duration of the study. Decisions will be made by the committee on the basis of scientific merit and strategic fit within the AOI. The intent is to fully fund 3-4 studies with an average study cost in our program of approximately $300,000 USD.

The following areas are of interest to Investigator Studies Program Committee:
Proposals aligned with the areas of interest below will be primarily assessed on their ability to be easily applicable & affordable in low resource settings:
  • Novel approaches, technologies or biomarkers to predict, rapidly diagnose, or treat puerperal sepsis (from membrane rupture to 42 days post-partum)
  • Affordable blood substitutes suitable for use in low resource settings (+/- heat stable)
    • Evaluation of methods to safely store blood or blood products which do not require refrigeration
  • Real-world characterization of oxytocin use in low resource settings through either prospective studies or retrospective reviews
    • Average number # of ampules used for a post-partum hemorrhage prevention (PPH) dose and/or a PPH treatment dose
    • Average failure rate of oxytoxin PPH prevention dose and need for follow-on uterotonics to treat continuing PPH
    • Average wastage of oxytoxin (due to product expiration, heat degradation, lack of potency, and /or lack of active ingredients/poor quality)
    • Average interval from the time of manufacture to time of clinical use of oxytocin
  • Novel approaches to accurately identify gestational age across the full pregnancy continuum (Day 1 to birth)
  • Novel technologies for uterine contraction monitoring which are easily applicable in low resource settings
  • Administration of tranexamic acid (TXA) as a prodrug or by other novel delivery mechanisms for use in post-partum hemorrhage
  • Identification and validation of biomarkers for pre-eclampsia or eclampsia with clinical utility at the time of admission

Please complete a full protocol and detailed budget via Visiontracker, the Company's on-line study management system. The proposals will be collectively reviewed and selected by the Merck for Mothers IISP Committee.

Grant Application

Contact Information

Joanne Woodland
Telephone: (267) 305-5423
E-Mail: joanne_woodland@merck.com

Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ USA All rights reserved. | Privacy | Terms of Use
© Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ USA Privacy | Terms of Use